Sector News

Sanofi and Evotec seal 250m-Euro strategic alliance

March 20, 2015
Life sciences
Sanofi and Evotec have now concluded negotiations over a five-year strategic alliance giving the German group 250 million Euros, including more than 40 million Euros upfront in cash.
 
The move will see Evotec acquire Sanofi’s troubled operations in Toulouse, to support collaborative research in drug discovery from screening to identification of preclinical candidates with the firm’s biotech, venture capital and academic partners. 
 
Evotec said it will provide a broad range of long-term drug discovery services to Sanofi over the next five years, centred on the core small-molecule discovery platforms in Toulouse, and will take over management of the French drugmaker’s global screening compound library.
 
And, in a “first-in class, ground-breaking ‘open innovation initiative’,” both groups will combine their libraries and offer them for screening to Evotec’s business partners, creating “one of the largest and most valuable sources of starting points for drug discovery with approx. 1,700,000 compounds available to screen”.
 
Elsewhere, Evotec and Sanofi will jointly push forward a portfolio of primarily cancer-related projects – including five advanced, preclinical projects and further discovery-stage assets – to Investigational New Drug status or other value inflection points before partnering them.
 
Werner Lanthaler, Evotec’s chief executive, said the transaction “supports our long-term strategic growth plans” and “brings significant value to [our] shareholders without the need for dilutive financing”, while Elias Zerhouni, President Global R&D for Sanofi, said it will “create a field of opportunities for our employees, while contributing to the vitality of the local ecosystem”.
 
By Selina McKee
 
Source: Pharma Times

Related News

September 23, 2020

Novartis, Siemens to develop blood tests for multiple sclerosis

Life sciences

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the companies […]

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]